Data completeness
0/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MECLAN is a topical cream formulation of meclocycline sulfosalicylate, a tetracycline-class antibiotic indicated for bacterial skin infections. The drug works by inhibiting bacterial protein synthesis through binding to the 30S ribosomal subunit. It is currently in pre-launch development under Johnson & Johnson sponsorship.
Pre-Launch
Early-stage product with minimal current commercial footprint; team building and launch planning phases will define near-term hiring and role expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
MECLAN presents a pre-launch career opportunity within Johnson & Johnson's dermatology or infection disease franchise. Joining the team now positions professionals for hands-on involvement in product launch strategy, market access, and commercial build-out.
Brand ManagerProduct Manager
Worked on MECLAN at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.